Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer
Authors:
Open Access
- 21 October 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1004351
Abstract
Background: The purpose of this study was to investigate the predictive value of tumor metabolic parameters in combination with secondary lymphoid metabolic parameters on positron emission tomography (PET)/computed tomography (CT) for immune checkpoint inhibitor (ICI) prognosis in advanced lung cancer.Methods: This study retrospectively included 125 patients who underwent 18F-fludeoxyglucose (FDG) PET/CT before ICI therapy, including 41 patients who underwent a second PET/CT scan during ICI treatment. The measured PET/CT parameters included tumor metabolism parameters [maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), total lesion glycolysis (TLG), and total metabolic tumor volume (TMTV)] and secondary lymphoid organ metabolism parameters [spleen-to-liver SUVmax ratio (SLR) and bone marrow-to-liver SUVmax ratio (BLR)]. The correlation of PET/CT metabolic parameters with early ICI treatment response, progression-free survival (PFS), and overall survival (OS) was analyzed.Results: Within a median follow-up of 28.7 months, there were 44 responders and 81 non-responders. The median PFS was 8.6 months (95% confidence interval (CI): 5.872–11.328), and the median OS was 20.4 months (95% CI: 15.526–25.274). Pretreatment tumor metabolic parameters were not associated with early treatment responses. The high bone marrow metabolism (BLR >1.03) was significantly associated with a shorter PFS (p = 0.008). Patients with a high TMTV (>168 mL) and high spleen metabolism (SLR >1.08) had poor OS (p = 0.019 and p = 0.018, respectively). Among the 41 patients who underwent a second PET/CT scan, the ΔSUVmax was significantly lower (p = 0.01) and the SLR was significantly higher (p = 0.0086) in the responders. Populations with low-risk characteristics (low TMTV, low SLR, and ΔSLR > 0) had the longest survival times.Conclusion: High pretreatment TMTV and SLR are associated with poor OS, and increased spleen metabolism after ICI therapy predicts treatment benefit. This indicates that the combination of tumor and spleen metabolic parameters is a valuable prognostic strategy.Keywords
Funding Information
- National Natural Science Foundation of China (81972864)
- National Natural Science Foundation of China (82172720)
- Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China (2019KJL001)
This publication has 45 references indexed in Scilit:
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor MicroenvironmentTrends in Immunology, 2016
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma settingInternational Immunopharmacology, 2014
- TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKɛ supports the anabolic demands of dendritic cell activationNature Immunology, 2014
- Origins of tumor-associated macrophages and neutrophilsProceedings of the National Academy of Sciences, 2012
- In vivo suppressive function of myeloid‐derived suppressor cells is limited to the inflammatory siteEuropean Journal of Immunology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Activated Akt promotes increased resting T cell size, CD28‐independent T cell growth, and development of autoimmunity and lymphomaEuropean Journal of Immunology, 2003
- Role of the spleen on immunosuppression in esophageal and gastric cancerSurgery Today, 1986